


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

ELIGIBILITY

CONCURRENT COMPONENTS OF VISIT

DISPOSITION



ALT = alanine aminotransferase
 LDH = lactate dehydrogenase

¹ Consider use of Vanderbilt's [ABCDE's approach to cardiovascular health](#)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

ELIGIBILITY

CONCURRENT COMPONENTS OF VISIT

DISPOSITION

AML patients
 4 years post
 diagnosis and
 in remission

RISK REDUCTION/ EARLY DETECTION

Patient education, counseling and screening:

- Lifestyle risk assessment¹
- Cancer screening²
- HPV vaccination as clinically indicated (see [HPV Vaccination algorithm](#))
- Screening for Hepatitis B and C as clinically indicated (see [Hepatitis B Virus \(HBV\) Screening and Management algorithm](#))
- Vaccinations³ as appropriate
 - Pneumococcus vaccines PCV13 followed by PPSV23 at least 8 weeks apart. Thereafter, only PPSV23 every 5 years.
 - Influenza vaccination yearly
 - Consider one dose of tetanus-diphtheria-pertussis (Tdap) vaccine as an adult if patient has not received Tdap previously and there are no contraindications. Thereafter tetanus-diphtheria (Td) vaccination every 10 years.
 - Zoster Vaccine Recombinant, Adjuvanted (Shingrix) can be considered for patients whose last chemotherapy treatment is greater than 6 months, has a shared patient-provider conversation regarding the vaccine, and meets ACIP criteria⁴
 - Recommendations for vaccination of household members
 - Patients should inform their providers about plans to travel outside of the US at least one month in advance for appropriate counseling and vaccinations

PSYCHOSOCIAL FUNCTIONING

Assess for the following as clinically indicated:

- Distress management (see [Distress Screening and Psychosocial Management algorithm](#))
- Relationship issues
- Access to primary health care
- Infertility
- Cognitive testing
- Fatigue
- Financial stressors

Refer or
 consult as
 indicated

ACIP = Advisory Committee on Immunization Practices

¹ See [Physical Activity](#), [Nutrition](#), and [Tobacco Cessation](#) algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

² Includes [breast](#), [cervical](#) (if appropriate), [colorectal](#), [liver](#), [lung](#), [pancreatic](#), [prostate](#) and [skin cancer](#) screening

³ Based on [Centers for Disease Control and Prevention \(CDC\) guidelines](#)

⁴ Adults age 50 years and older with a history of chickenpox or shingles

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

SUGGESTED READINGS

- Centers for Disease Control and Prevention. (2017). *Pneumococcal Vaccination*. Retrieved from http://www.cdc.gov/vaccines/vpd-vac/pneumo/default.htm?s_cid=cs_797
- Centers for Disease Control and Prevention. (2021). *Recommended adult immunization schedule for ages 19 years or older, United States, 2021*. Retrieved from <https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf>
- Cheng, M. J., Hourigan, C. S., & Smith T. J. (2014). Adult Acute Myeloid Leukemia Long-term Survivors. *Journal of Leukemia*, 2(2), 26855. doi:10.4172/2329-6917.1000135
- Dagnew, A. F., Ilhan, O., Lee, W.-S., Woszczyk, D., Kwak, J.-Y., Bowcock, S., . . . Oostvogels, L. (2019). Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis. *The Lancet Infectious Diseases*, 19(9), 988-1000. [http://dx.doi.org/10.1016/S1473-3099\(19\)30163-X](http://dx.doi.org/10.1016/S1473-3099(19)30163-X)
- Denlinger, C. S., Sanft, T., Baker, K. S., Broderick, G., Demark-Wahnefried, W., Friedman, D. L., . . . Freedman-Cass, D. A. (2018). Survivorship, version 2.2018, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*, 16(10), 1216-1247. doi:10.6004/jnccn.2018.0078
- Ghimire, K. B. & Shah, B. K. (2014). Second primary malignancies in adult acute myeloid leukemia-A US population-based study. *Anticancer Research*, 34(7), 3855-3859. Retrieved from <http://ar.iiarjournals.org/content/34/7/3855.full.pdf+html>
- Ghodraty-Jabloo, V., Alibhai, S. M., Breunis, H., & Puts, M. T. (2015). One day at a time: Improving the patient experience during and after intensive chemotherapy for younger and older AML patients. *Leukemia Research*, 39(2), 192-197. doi:10.1016/j.leukres.2014.11.028
- Kim, D. K., Bridges, C. B., & Harriman, K. H. (2015). Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2015. *Morbidity and Mortality Weekly Report*, 64(4), 91-92. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584856/pdf/91-92.pdf>
- Leak Bryant, A., Lee Walton, A., Shaw-Kotok, J., Mayer, D. K., & Reeve, B. B. (2015). Patient-reported symptoms and quality of life in adults with acute leukemia: A systematic review. *Oncology Nursing Forum*, 42(2), E91-E101. doi:10.1188/15.ONF.E91-E101
- Mohamedali, H. Z., Breunis, H., Panju, A., & Alibhai S. M. H. (2010). Information needs, decisional regret and satisfaction of older and younger adults with acute myeloid leukemia. *Journal of Geriatric Oncology*, 1(2), 66-72. <https://doi.org/10.1016/j.jgo.2010.06.002>
- National Comprehensive Cancer Network. (2021). Acute Myeloid Leukemia (Version 3.2021). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
- Romero, D. (2015). Haematological cancer: Improving prediction of relapse risk. *Nature Reviews. Clinical Oncology*, 12(10), 564. doi:10.1038/nrclinonc.2015.156
- Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., . . . Kang, I. (2013). 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clinical Infectious Diseases*, 59(1) 144. <https://doi.org/10.1093/cid/ciu257>
- Vanderbilt Cardio-Oncology Program. (2017). *Know Your ABCDE's*. Retrieved from <http://www.cardioonc.org/2017/08/29/know-your-abcs/>

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.*

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Leukemia Survivorship workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads

Alessandra Ferrajoli, MD (Leukemia)
Musa Yilmaz, MD (Leukemia)

Workgroup Members

Ella Ariza Heredia, MD (Infectious Diseases)
Naval Daver, MD (Leukemia)
Wendy Garcia, BS♦
Katherine Gilmore, MHP (Cancer Survivorship)
Tapan Kadia, MD (Leukemia)
Thoa Kazantsev, MSN, RN, OCN♦
Nicholas J. Short, MD (Leukemia)

♦Clinical Effectiveness Development Team